

AMENDMENT TO THE CLAIMS

Claims 1-30 (Canceled).

31. (Previously Presented) A method of treating prostate cancer in a mammal, comprising:
 - administering a quantity of R-etodolac on an R-etodolac periodic basis;
 - and
 - administering a quantity of a recombinant humanized monoclonal antibody 2C4 to said mammal on a 2C4 periodic basis.
32. (Previously Presented) The method of claim 31, wherein the 2C4 periodic basis is twice weekly.
33. (Previously Presented) The method of claim 31, wherein the R-etodolac periodic basis is daily.
34. (New) The method of claim 31, wherein the quantity of the R-etodolac is from about 100 to about 500 mg/kg of said mammal.
35. (New) The method of claim 31, wherein the quantity of the recombinant humanized monoclonal antibody 2C4 is from about 5 to about 40 mg/kg of said mammal.
36. (New) The method of claim 31, wherein administering the quantity of the R-etodolac and administering the quantity of the recombinant humanized monoclonal antibody 2C4 further comprises using a delivery technique independently selected from the group consisting of intraperitoneal, oral gavage, intravenous, sublingual, topical, intramuscular, intra-arterial, intramedullar, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, parenteral, and rectal.

37. (New) A method of treating prostate cancer in a mammal, comprising:
- providing a quantity of R-etodolac and a quantity of a recombinant humanized monoclonal antibody 2C4;
 - administering the quantity of R-etodolac to said mammal; and
 - administering the quantity of the recombinant humanized monoclonal antibody 2C4 to said mammal.